Norway· NO-ID_A462226E-C04D-402C-B8F9-EF9E4F4A4A08
Voraxaze
A glucarpidase product containing glucarpidase, registered in Norway by SERB SAS. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Glucarpidase is registered in 12 of 19 countries.
Countries holding a registration under ATC V03AF09 (glucarpidase), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Glucarpidase · ATC V03AF09
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Glucarpidase
- Manufacturer
- SERB SAS
- Country
- Norway (NO)
- ATC code
- V03AF09
- ATC class
- Glucarpidase
- Defined daily dose
- 3.5 TSD, E
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_A462226E-C04D-402C-B8F9-EF9E4F4A4A08
- no_varenummer3867751000NOK 353346
- gtin5060311320209
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for glucarpidase.
Graded by severity as the source publishes them — 8 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glucarpidase · interactions on record
8 records
- 8 moderate
Most severe, free to view
- TrimethoprimJ01EA01moderate
- PemetrexedL01BA04moderate
- PralatrexateL01BA05moderate
- TrimetrexateP01AX07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glucarpidase in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomVoraxaze 1,000unit powder for solution for injection vialsProtherics Medicines Development Ltd
- CzechiaVORAXAZESERB SAS, Paříž
- SpainVORAXAZE 1.000 UNIDADES POLVO PARA SOLUCION INYECTABLESerb
- FinlandVoraxazeSerb
- FranceVORAXAZE 1000 unités, poudre pour solution injectableSERB
- IrelandVoraxaze 1,000 units powder for solution for injectionSerb S.A.S.
- IcelandVoraxazeSERB SAS
- Japanグルカルピダーゼ（遺伝子組換え）大原薬品工業
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Voraxaze
- Liechtenstein · Voraxaze
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9ec3f699-57ef-42b0-bd09-5f8406012535 GET /v1/drugs/9ec3f699-57ef-42b0-bd09-5f8406012535?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Glukarpidase",
"merkevare_id": "ID_A462226E-C04D-402C-B8F9-EF9E4F4A4A08",
"name_form_strength": "Voraxaze pulv til inj væske, oppl 1 000 E/ml",
"prescription_group": "C"
}See everything about glucarpidase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.